Nicole Seminara, MD
Dermatology · Huntersville, NCNPI 1437441003
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,136,466 of the $1,420,581 with a category attached, or 80.0%. 32 manufacturers reported payments, led by AbbVie at 31.1% of the total. 2025 is the largest year on record at $543,711, more than ten times the $742 reported in 2019. Among dermatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,929 payments — averaging $736.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$442K
- Johnson & Johnson$351K
- Lilly USA, LLC$154K
- Pfizer$125K
- Janssen Scientific Affairs, LLC$103K
- UCB, Inc.$69K
- plus $177K from 26 others
Across 143 payments — averaging $5153.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$193K
- Novartis$159K
- Eli Lilly$143K
- AbbVie$129K
- Incyte Corporation$65K
- Sun Pharmaceutical Industries Inc.$19K
- plus $29K from 2 others
What the payments were for
- Consulting fees$132,0779%
- Speaking & faculty fees$1,136,46680%
- Travel & lodging$113,7558%
- Food & beverage$37,9123%
- Education$3720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 436 | $441,660 |
| Johnson & Johnson(2 entities) | 376 | $350,985 |
| Lilly USA, LLC | 299 | $153,938 |
| Pfizer | 159 | $125,164 |
| Janssen Scientific Affairs, LLC | 108 | $103,129 |
| UCB, Inc. | 69 | $68,865 |
| Galderma Laboratories, L.p. | 83 | $64,595 |
| Organon | 55 | $58,259 |
| Sun Pharmaceutical Industries Inc. | 60 | $28,778 |
| Novartis | 53 | $11,231 |
| Sanofi | 49 | $8,169 |
| Sanofi US Services Inc. | 3 | $2,145 |
| Dermavant Sciences, Inc. | 68 | $818 |
| Medimetriks Pharmaceuticals, Inc. | 18 | $520 |
| Regeneron Healthcare Solutions, Inc. | 13 | $472 |
| E.r. Squibb & Sons, L.L.C. | 17 | $347 |
| LEO Pharma Inc. | 13 | $293 |
| Blueprint Medicines Corporation | 2 | $159 |
| Amgen | 6 | $151 |
| Incyte Corporation | 7 | $135 |
| Almirall LLC | 5 | $109 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $108 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $96 |
| Arcutis Biotherapeutics, Inc. | 6 | $89 |
| Boehringer Ingelheim | 4 | $85 |
| Mayne Pharma Commercial LLC | 4 | $78 |
| Journey Medical Corporation | 3 | $61 |
| Biofrontera Inc. | 2 | $39 |
| VYNE Pharmaceuticals Inc. | 2 | $37 |
| Dermira, Inc. | 1 | $33 |
| Organogenesis Inc. | 1 | $20 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,420,581 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 46 | $296,888 |
| Cosentyx Unoready PenSecukinumab | 12 | $166,558 |
| TremfyaGuselkumab | 11 | $146,328 |
| Dupixent PenDupilumab | 36 | $141,671 |
| HumiraAdalimumab | 11 | $74,181 |
| Dupixent SyringeDupilumab | 14 | $53,831 |
| Clobetasol Propionate | 120 | $6,293 |
| Tacrolimus | 21 | $3,094 |
| Doxycycline Hyclate | 134 | $3,076 |
| Triamcinolone Acetonide | 237 | $2,846 |
| Fluorouracil | 24 | $2,148 |
| Desonide | 36 | $1,962 |
| Finasteride | 181 | $1,510 |
| Dutasteride | 53 | $1,486 |
| Metronidazole | 29 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $441,660 | $371,06957 claims |
| Johnson & JohnsonTremfya | $350,985 | $146,32811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Huntersville
- William HooverHuntersville$52K
- Steven FeldmanWinston Salem$3.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- George MagelHickory$554K
- Muneeb ShahClinton$451K
- John SoderbergCary$398K
- Rosalyn GeorgeWilmington$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.